Cerys Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 11-12-2024
- Paid Up Capital ₹ 3.30 M
as on 11-12-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 62.70%
(FY 2022)
- Profit -886.60%
(FY 2022)
- Ebitda -869.70%
(FY 2022)
- Net Worth -1213.31%
(FY 2022)
- Total Assets 75.27%
(FY 2022)
About Cerys Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.30 M, as per Ministry of Corporate Affairs (MCA) records.
Raja Ramasamy, Vikram Bhadoriya, Devendra Tiwari, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74999MH2020PTC340993
- Company No.
340993
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jun 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Cerys Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raja Ramasamy  | Director | 25-Jun-2020 | Current |
| Vikram Bhadoriya | Director | 10-Feb-2022 | Current |
| Devendra Tiwari | Director | 24-Apr-2021 | Current |
| Amit Sharma | Director | 25-Jun-2020 | Current |
| Anurudra Mukherjee | Director | 25-Jun-2020 | Current |
Financial Performance of Cerys Pharmaceuticals.
Cerys Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 62.7% increase. The company also saw a substantial fall in profitability, with a 886.6% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1213.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cerys Pharmaceuticals?
In 2021, Cerys Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Akshya Multimedia Publication Private LimitedActive 4 years 4 monthsRaja Ramasamy is a mutual person
Shrigarud Developers Private LimitedActive 2 years 7 monthsRaja Ramasamy, Devendra Tiwari and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cerys Pharmaceuticals?
Cerys Pharmaceuticals has a workforce of 24 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cerys Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cerys Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
